Evolus PE Ratio 2016-2025 | EOLS
Current and historical p/e ratio for Evolus (EOLS) from 2016 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Evolus PE ratio as of August 20, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Evolus PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-08-20 | 7.23 | 0.00 | |
| 2025-06-30 | 9.21 | $-0.98 | 0.00 |
| 2025-03-31 | 12.03 | $-0.89 | 0.00 |
| 2024-12-31 | 11.04 | $-0.81 | 0.00 |
| 2024-09-30 | 16.20 | $-0.91 | 0.00 |
| 2024-06-30 | 10.85 | $-0.91 | 0.00 |
| 2024-03-31 | 14.00 | $-1.05 | 0.00 |
| 2023-12-31 | 10.53 | $-1.09 | 0.00 |
| 2023-09-30 | 9.14 | $-1.11 | 0.00 |
| 2023-06-30 | 7.27 | $-1.17 | 0.00 |
| 2023-03-31 | 8.46 | $-1.27 | 0.00 |
| 2022-12-31 | 7.51 | $-1.32 | 0.00 |
| 2022-09-30 | 8.05 | $-1.42 | 0.00 |
| 2022-06-30 | 11.60 | $-1.41 | 0.00 |
| 2022-03-31 | 11.22 | $-1.30 | 0.00 |
| 2021-12-31 | 6.51 | $-0.83 | 0.00 |
| 2021-09-30 | 7.62 | $-3.78 | 0.00 |
| 2021-06-30 | 12.65 | $-3.77 | 0.00 |
| 2021-03-31 | 12.99 | $-4.09 | 0.00 |
| 2020-12-31 | 3.36 | $-4.84 | 0.00 |
| 2020-09-30 | 3.91 | $-2.03 | 0.00 |
| 2020-06-30 | 5.30 | $-2.67 | 0.00 |
| 2020-03-31 | 4.15 | $-3.41 | 0.00 |
| 2019-12-31 | 12.17 | $-3.22 | 0.00 |
| 2019-09-30 | 15.62 | $-3.21 | 0.00 |
| 2019-06-30 | 14.62 | $-2.71 | 0.00 |
| 2019-03-31 | 22.57 | $-2.03 | 0.00 |
| 2018-12-31 | 11.90 | $-1.93 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.461B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.435B | 26.79 |
| Boston Scientific (BSX) | United States | $153.732B | 36.66 |
| Stryker (SYK) | United States | $149.077B | 30.35 |
| EssilorLuxottica (ESLOY) | France | $146.011B | 0.00 |
| Medtronic (MDT) | Ireland | $115.234B | 16.26 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.493B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.717B | 24.97 |
| ResMed (RMD) | United States | $41.881B | 29.95 |
| Agilent Technologies (A) | United States | $34.119B | 22.24 |
| GE HealthCare Technologies (GEHC) | United States | $33.772B | 15.87 |
| Terumo (TRUMY) | Japan | $27.820B | 32.97 |
| Koninklijke Philips (PHG) | Netherlands | $26.548B | 17.56 |
| Insulet (PODD) | United States | $23.052B | 77.24 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.663B | 13.15 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.153B | 0.00 |
| Baxter (BAX) | United States | $12.496B | 9.65 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.804B | 28.67 |
| Lantheus Holdings (LNTH) | United States | $3.750B | 10.14 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.442B | 24.08 |
| Perrigo (PRGO) | Ireland | $3.247B | 8.11 |
| Prestige Consumer Healthcare (PBH) | United States | $3.219B | 14.28 |
| ICU Medical (ICUI) | United States | $3.055B | 20.80 |
| Haemonetics (HAE) | United States | $2.616B | 11.68 |
| LeMaitre Vascular (LMAT) | United States | $2.158B | 46.28 |
| QuidelOrtho (QDEL) | United States | $1.816B | 11.43 |
| AtriCure (ATRC) | United States | $1.781B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.676B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.566B | 67.25 |
| Phibro Animal Health (PAHC) | United States | $1.291B | 16.50 |
| AdaptHealth (AHCO) | United States | $1.279B | 18.17 |
| Neogen (NEOG) | United States | $1.219B | 19.34 |
| Acuren (TIC) | United States | $1.209B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.176B | 2454.00 |
| Tilray Brands (TLRY) | Canada | $1.167B | 0.00 |
| Valneva SE (VALN) | France | $0.975B | 0.00 |
| InMode (INMD) | Israel | $0.896B | 8.29 |
| Kestra Medical Technologies (KMTS) | United States | $0.805B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.639B | 0.00 |
| SNDL (SNDL) | Canada | $0.552B | 0.00 |
| ZimVie (ZIMV) | United States | $0.534B | 20.60 |
| Surmodics (SRDX) | United States | $0.534B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.506B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.501B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 16.10 |
| CeriBell (CBLL) | United States | $0.432B | 0.00 |
| Owens & Minor (OMI) | United States | $0.414B | 3.67 |
| Capricor Therapeutics (CAPR) | United States | $0.351B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.315B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.300B | 0.00 |
| Omeros (OMER) | United States | $0.297B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.275B | 0.00 |
| Brainsway (BWAY) | Israel | $0.273B | 55.65 |
| Viemed Healthcare (VMD) | United States | $0.270B | 20.44 |
| Aurora Cannabis (ACB) | Canada | $0.269B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.262B | 0.00 |
| High Tide (HITI) | Canada | $0.248B | 0.00 |
| Quanterix (QTRX) | United States | $0.234B | 0.00 |
| Cerus (CERS) | United States | $0.228B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.217B | 0.00 |
| Exagen (XGN) | United States | $0.212B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Organigram Global (OGI) | Canada | $0.204B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.187B | 15.61 |
| TriSalus Life Sciences (TLSI) | United States | $0.176B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.157B | 19.38 |
| Biote (BTMD) | United States | $0.149B | 4.95 |
| Jushi Holdings (JUSHF) | United States | $0.103B | 0.00 |
| Jin Medical (ZJYL) | China | $0.095B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.094B | 0.00 |
| MacroGenics (MGNX) | United States | $0.094B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.09 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.084B | 0.00 |
| Apyx Medical (APYX) | United States | $0.075B | 0.00 |
| Safety Shot (SHOT) | United States | $0.071B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.064B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.053B | 31.05 |
| Veru (VERU) | United States | $0.047B | 0.00 |
| Zynex (ZYXI) | United States | $0.047B | 0.00 |
| Nephros (NEPH) | United States | $0.044B | 34.42 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 13.98 |
| Trinity Biotech (TRIB) | Ireland | $0.025B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |